Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R. IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.

Sheleme T, Mamo G, Melaku T, Sahilu T. Prevalence, patterns and predictors of Chronic complications of Diabetes Mellitus at a large Referral Hospital in Ethiopia: a prospective observational study. Diabetes Metab Syndr Obes. 2020;13:4909–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fox CS. Cardiovascular Disease Risk factors, type 2 diabetes Mellitus, and the Framingham Heart Study. Trends Cardiovasc Med. 2010;20(3):90–5.

Article  PubMed  PubMed Central  Google Scholar 

Schernthaner G. Cardiovascular mortality and morbidity in type-2 diabetes mellitus. Diabetes Res Clin Pract. 1996;3:S3–13.

Article  Google Scholar 

Zenu S, Abebe E, Dessie Y, Debalke R, Berkessa T, Reshad M. Co-occurrence of behavioral risk factors of non-communicable diseases and Social Determinants among adults in Urban Centers of Southwestern Ethiopia in 2020: a community-based cross-sectional study. J Multidiscip Healthc. 2021;14:1561–70.

Article  PubMed  PubMed Central  Google Scholar 

Mouodi S, Hosseini SR, Graham Cumming R, Bijani A, Esmaeili H, Ghadimi R. Physiological risk factors for cardiovascular disease in middle-aged (40–60 year) adults and their association with dietary intake, Northern Iran. Casp J Intern Med. 2019;10(1):55–64.

Google Scholar 

Pijls BG, Jolani S, Atherley A, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021;11:e044640.

Article  PubMed  Google Scholar 

Nicula M, Pacala N, Stef L, Pet I, Dronca D, Gherbon A, Ahmadi M. In vivo experiments of Natural products Protection of Antagonistic effects of lead on Iron. Rev Chim. 2017;68:12.

Google Scholar 

Jukarainen S, Kiiskinen T, Kuitunen S, et al. Genetic risk factors have a substantial impact on healthy life years. Nat Med. 2022;28:1893–901.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adisasmito W, Amir V, Atin A, et al. Geographic and socioeconomic disparity in cardiovascular risk factors in Indonesia: analysis of the Basic Health Research. BMC Public Health. 2020;20:1004.

Article  PubMed  PubMed Central  Google Scholar 

Xu D, Chandler O, Wee C, Ho C, Affandi JS, Yang D, Liao X, Chen W, Li Y, Reid C, Xiao H. Sodium-glucose Cotransporter-2 inhibitor (SGLT2i) as a primary Preventative Agent in the healthy individual: a need of a future Randomised Clinical Trial? Front Med (Lausanne). 2021;8:712671.

Article  PubMed  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular events (DECLARE)–TIMI 58 Trial. Am Heart J. 2018;200:83–9.

Article  CAS  PubMed  Google Scholar 

Nuttall FQ, MD, PhD. Body Mass Index: obesity, BMI, and Health. Nutr Today. 2015;50(3):117–28.

Article  PubMed  PubMed Central  Google Scholar 

Ross R, Neeland IJ, Yamashita S, Shai I, Seidell J, Magni P, Santos RD, Arsenault B, Cuevas A, Hu FB, Griffin BA, Zambon A, Barter P, Fruchart JC, Eckel RH, Matsuzawa Y, Després JP. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on visceral obesity. Nat Rev Endocrinol. 2020;16(3):177–89.

Article  PubMed  PubMed Central  Google Scholar 

Knuuti J, Wijns W, Saraste A, Capodanno D, ESC Scientific Document Group. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes: the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407–77.

Article  PubMed  Google Scholar 

American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes. Diabetes Care. 2019;42(1):S13–28.

Article  Google Scholar 

Ren F, Li M, Xu H, Qin X, Teng Y. Urine albumin-to-creatinine ratio within the normal range and risk of hypertension in the general population: a meta-analysis. J Clin Hypertens (Greenwich). 2021;23(7):1284–90.

Article  CAS  PubMed  Google Scholar 

Fischbach F. Immunodiagnostics studies. A Manual of Laboratory and Diagnostics tests. 8 ed. USA: Lippincott Williams & Wilkins; 2009. p. 642.

Google Scholar 

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members; Document Reviewers. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.

Article  PubMed  Google Scholar 

Gardete-Correia L, Boavida J, Raposo J, Mesquita A, Fona C, Carvalho R, et al. First diabetes prevalence study in Portugal: PREVADIAB study. Diabet Medicine: J Br Diabet Association. 2010;27:879–81.

Article  CAS  Google Scholar 

Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin for primary and Secondary Prevention of Cardiovascular Events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137(4):323–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baldé NM, Diallo I, Baldé MD, Barry IS, Kaba L, Diallo MM, et al. Diabetes and impaired fasting glucose in rural and urban populations in Futa Jallon (Guinea): prevalence and associated risk factors. Diabetes Metab. 2007;33(2):114–20.

Article  PubMed  Google Scholar 

Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and Cardiovascular Risk: lessons learned from the EMPA-REG OUTCOME Study. Diabetes Care. 2016;39(5):717.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oliva RV Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 2014;8:330–9.

Tikkanen I, Narko K, Zeller C, et al. EMPA-REG BP investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420–8.

Article  CAS  PubMed  Google Scholar 

Feder D, de Fatima Veiga Gouveia MR, Govato TCP, Nassis CDZ. SGLT2 inhibitors and the mechanisms involved in weight loss. Curr Pharmacol Rep. 2020;6(6):346–53.

Article  CAS  Google Scholar 

Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, Sarigianni M, Matthews DR, Tsapas A. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–74.

Article  PubMed  Google Scholar 

Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, Tanizawa Y, Araki E, Ueda M, Suganami H, Watanabe D. Tofogliflozin 003 Study Group. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65.

Article  PubMed  PubMed Central  Google Scholar 

Bashier A, Khalifa AA, Rashid F, Abdelgadir EI, Al Qaysi AA, Ali R, et al. Efficacy and safety of SGLT2 inhibitors in reducing Glycated Hemoglobin and Weight in Emirati patients with type 2 diabetes. J Clin Med Res. 2017;4:26.

Google Scholar 

Hirai T, Kawagoe Y, Kei M, Ogawa R, Itoh T. Clinical predictors of the hypoglycemic effect of sodium–glucose co-transporter-2 inhibitors in Hyperuricemic patients: a Retrospective descriptive observational study. Biol Pharm Bull. 2020;43(5):782–7.

Article  CAS  PubMed  Google Scholar 

Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic akita mice. Am J Physiology-Renal Physiol. 2014;306(2):F194–204.

Article  CAS  Google Scholar 

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.

Article  CAS  PubMed  Google Scholar 

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.

Article  CAS  PubMed  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.

Article  CAS  PubMed  Google Scholar 

Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. New Engl J Med. 2020;28:96.

Google Scholar 

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.

Article  CAS  PubMed  Google Scholar 

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;28:457.

Google Scholar 

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, et al. DAPA-HF Trial committees and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.

Article  CAS  PubMed  Google Scholar 

Szekeres Z, Toth K, Szabados E. The effects of SGLT2 inhibitors on lipid metabolism. Metabolites. 2021;11(2):87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hayashi T, et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitaglipt